WO2006023544A3 - Therapeutic uses of inhibitors of rtp801 - Google Patents

Therapeutic uses of inhibitors of rtp801 Download PDF

Info

Publication number
WO2006023544A3
WO2006023544A3 PCT/US2005/029236 US2005029236W WO2006023544A3 WO 2006023544 A3 WO2006023544 A3 WO 2006023544A3 US 2005029236 W US2005029236 W US 2005029236W WO 2006023544 A3 WO2006023544 A3 WO 2006023544A3
Authority
WO
WIPO (PCT)
Prior art keywords
rtp801
inhibitors
therapeutic uses
inhibition
protein
Prior art date
Application number
PCT/US2005/029236
Other languages
French (fr)
Other versions
WO2006023544A2 (en
Inventor
Elena Feinstein
Klaus Giese
Joerg Kaufmann
Original Assignee
Quark Biotech Inc
Atugen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EA200700333A priority Critical patent/EA012799B1/en
Priority to PL05786796T priority patent/PL1791568T3/en
Priority to MX2007002043A priority patent/MX2007002043A/en
Priority to BRPI0514395-0A priority patent/BRPI0514395A/en
Priority to NZ553162A priority patent/NZ553162A/en
Priority to JP2007527969A priority patent/JP4468989B2/en
Priority to CN2005800349685A priority patent/CN101123994B/en
Priority to DK05786796.2T priority patent/DK1791568T3/en
Priority to ES05786796T priority patent/ES2390085T3/en
Priority to KR1020097022383A priority patent/KR101094617B1/en
Priority to AU2005277508A priority patent/AU2005277508B2/en
Priority to EP11153604.1A priority patent/EP2319925B1/en
Priority to CA2577423A priority patent/CA2577423C/en
Priority to AP2007003921A priority patent/AP2007003921A0/en
Application filed by Quark Biotech Inc, Atugen Ag filed Critical Quark Biotech Inc
Priority to EP05786796A priority patent/EP1791568B1/en
Publication of WO2006023544A2 publication Critical patent/WO2006023544A2/en
Priority to IL181238A priority patent/IL181238A/en
Priority to TNP2007000063A priority patent/TNSN07063A1/en
Priority to NO20071240A priority patent/NO342934B1/en
Publication of WO2006023544A3 publication Critical patent/WO2006023544A3/en
Priority to HK08105809.2A priority patent/HK1111088A1/en
Priority to IL212985A priority patent/IL212985A0/en
Priority to IL243669A priority patent/IL243669B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/054—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function
    • A01K2217/058—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function due to expression of inhibitory nucleic acid, e.g. siRNA, antisense
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification

Abstract

The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases and respiratory conditions based upon inhibition of the RTP801 gene and/or protein.
PCT/US2005/029236 2004-08-16 2005-08-16 Therapeutic uses of inhibitors of rtp801 WO2006023544A2 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
EP11153604.1A EP2319925B1 (en) 2004-08-16 2005-08-16 Therapeutic uses of inhibitors of RTP801
MX2007002043A MX2007002043A (en) 2004-08-16 2005-08-16 Therapeutic uses of inhibitors of rtp801.
BRPI0514395-0A BRPI0514395A (en) 2004-08-16 2005-08-16 therapeutic use of rtp801 inhibitors
NZ553162A NZ553162A (en) 2004-08-16 2005-08-16 Double stranded siRNA compounds that inhibit RRTP801
JP2007527969A JP4468989B2 (en) 2004-08-16 2005-08-16 Use of RTP801 inhibitors for therapy
CN2005800349685A CN101123994B (en) 2004-08-16 2005-08-16 Therapeutic uses of inhibitors of rtp801
DK05786796.2T DK1791568T3 (en) 2004-08-16 2005-08-16 THERAPEUTIC APPLICATIONS OF INHIBITORS OF RTP801
ES05786796T ES2390085T3 (en) 2004-08-16 2005-08-16 Therapeutic uses of RTP801 inhibitors
PL05786796T PL1791568T3 (en) 2004-08-16 2005-08-16 Therapeutic uses of inhibitors of rtp801
AU2005277508A AU2005277508B2 (en) 2004-08-16 2005-08-16 Therapeutic uses of inhibitors of RTP801
KR1020097022383A KR101094617B1 (en) 2004-08-16 2005-08-16 Therapeutic uses of inhibitors of rtp801
EA200700333A EA012799B1 (en) 2004-08-16 2005-08-16 Therapeutic uses of inhibitors of rtp801
AP2007003921A AP2007003921A0 (en) 2004-08-16 2005-08-16 Therapeutic uses of inhibitors of rtp801
CA2577423A CA2577423C (en) 2004-08-16 2005-08-16 Therapeutic uses of inhibitors of rtp801
EP05786796A EP1791568B1 (en) 2004-08-16 2005-08-16 Therapeutic uses of inhibitors of rtp801
IL181238A IL181238A (en) 2004-08-16 2007-02-08 Sirna molecules that inhibit rtp801 gene expression and therapeutic uses thereof
TNP2007000063A TNSN07063A1 (en) 2004-08-16 2007-02-15 THERAPEUTIC USES OF RTP801 INHIBITORS
NO20071240A NO342934B1 (en) 2004-08-16 2007-03-07 THERAPEUTIC USES OF RTP801 INHIBITORS
HK08105809.2A HK1111088A1 (en) 2004-08-16 2008-05-26 Therapeutic uses of inhibitors of rtp801 rtp801
IL212985A IL212985A0 (en) 2004-08-16 2011-03-21 Therapeutic uses of inhibitors of rtp801
IL243669A IL243669B (en) 2004-08-16 2016-01-18 Sirna tp801 inhibitors for use in combination with vegf inhibitors or vegf-receptor1 inhibitors

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
EP04019405.2 2004-08-16
EP04019405 2004-08-16
US60198304P 2004-08-17 2004-08-17
US60/601,983 2004-08-17
US60466804P 2004-08-25 2004-08-25
US60/604,668 2004-08-25
US60978604P 2004-09-14 2004-09-14
US60/609,786 2004-09-14
US63865904P 2004-12-22 2004-12-22
US60/638,659 2004-12-22
US66423605P 2005-03-22 2005-03-22
US60/664,236 2005-03-22
US68894305P 2005-06-08 2005-06-08
US60/688,943 2005-06-08

Publications (2)

Publication Number Publication Date
WO2006023544A2 WO2006023544A2 (en) 2006-03-02
WO2006023544A3 true WO2006023544A3 (en) 2007-05-31

Family

ID=35968125

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/029236 WO2006023544A2 (en) 2004-08-16 2005-08-16 Therapeutic uses of inhibitors of rtp801

Country Status (20)

Country Link
US (4) US7741299B2 (en)
EP (2) EP1791568B1 (en)
JP (1) JP4468989B2 (en)
KR (2) KR101094617B1 (en)
CN (1) CN101123994B (en)
AP (1) AP2007003921A0 (en)
AU (1) AU2005277508B2 (en)
BR (1) BRPI0514395A (en)
CA (1) CA2577423C (en)
DK (1) DK2319925T3 (en)
EA (1) EA012799B1 (en)
HK (1) HK1111088A1 (en)
IL (3) IL181238A (en)
MA (1) MA28802B1 (en)
MX (1) MX2007002043A (en)
NO (1) NO342934B1 (en)
NZ (1) NZ553162A (en)
PL (1) PL1791568T3 (en)
TN (1) TNSN07063A1 (en)
WO (1) WO2006023544A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227956B2 (en) 2013-04-17 2016-01-05 Pfizer Inc. Substituted amide compounds
US9433684B2 (en) 2008-08-19 2016-09-06 Nektar Therapeutics Conjugates of small-interfering nucleic acids
KR101672563B1 (en) 2008-10-22 2016-11-03 쿠아크 파마수티칼스 인코퍼레이티드 Methods for treating eye disorders

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1857547B2 (en) 2002-08-05 2020-12-02 Silence Therapeutics GmbH Further novel forms of interfering RNA molecules
MXPA05004134A (en) * 2002-10-18 2005-10-05 Atugen Ag Factor involved in metastasis and uses thereof.
DE202004021946U1 (en) 2003-09-12 2013-05-29 Vessix Vascular, Inc. Selectable eccentric remodeling and / or ablation of atherosclerotic material
KR101094617B1 (en) 2004-08-16 2011-12-15 사일런스 테라퓨틱스 아게 Therapeutic uses of inhibitors of rtp801
US8396548B2 (en) 2008-11-14 2013-03-12 Vessix Vascular, Inc. Selective drug delivery in a lumen
US9713730B2 (en) 2004-09-10 2017-07-25 Boston Scientific Scimed, Inc. Apparatus and method for treatment of in-stent restenosis
AU2005288522B2 (en) 2004-09-28 2012-06-28 Quark Pharmaceuticals, Inc. Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
US7825099B2 (en) 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
DOP2007000015A (en) * 2006-01-20 2007-08-31 Quark Biotech Inc THERAPEUTIC USES OF RTP801 INHIBITORS
US7910566B2 (en) * 2006-03-09 2011-03-22 Quark Pharmaceuticals Inc. Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
US8019435B2 (en) 2006-05-02 2011-09-13 Boston Scientific Scimed, Inc. Control of arterial smooth muscle tone
EP2026843A4 (en) 2006-06-09 2011-06-22 Quark Pharmaceuticals Inc Therapeutic uses of inhibitors of rtp801l
JP2008167739A (en) * 2006-06-14 2008-07-24 National Institute Of Advanced Industrial & Technology Modified type double stranded rna having high rna interference activity
EP2954868A1 (en) 2006-10-18 2015-12-16 Vessix Vascular, Inc. Tuned rf energy and electrical tissue characterization for selective treatment of target tissues
JP5559539B2 (en) 2006-10-18 2014-07-23 べシックス・バスキュラー・インコーポレイテッド System that induces desirable temperature effects on body tissue
ES2560006T3 (en) 2006-10-18 2016-02-17 Vessix Vascular, Inc. Induction of desirable temperature effects on body tissue
JP2010507387A (en) * 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド Novel siRNA and method of using the same
EP2137205A2 (en) * 2007-02-26 2009-12-30 Quark Pharmaceuticals, Inc. Inhibitors of rtp801 and their use in disease treatment
WO2008104978A2 (en) * 2007-02-28 2008-09-04 Quark Pharmaceuticals, Inc. Novel sirna structures
US7812002B2 (en) * 2007-03-21 2010-10-12 Quark Pharmaceuticals, Inc. Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer
EP2152316A4 (en) * 2007-04-26 2011-03-23 Quark Pharmaceuticals Inc Therapeutic delivery of inhibitory nucleic acid molecules to the respiratory system
DK2170403T3 (en) * 2007-06-27 2014-06-16 Quark Pharmaceuticals Inc Compositions and Methods for Inhibiting the Expression of Proapoptotic Genes
US20090062309A1 (en) * 2007-08-28 2009-03-05 Antonio Delgado-Almeida Therapeutic compositions for the treatment of cardiovascular diseases and methods for use therefor
WO2009044392A2 (en) * 2007-10-03 2009-04-09 Quark Pharmaceuticals, Inc. Novel sirna structures
US20110105584A1 (en) * 2007-12-12 2011-05-05 Elena Feinstein Rtp80il sirna compounds and methods of use thereof
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof
MX2010010303A (en) * 2008-03-20 2010-10-20 Quark Pharmaceuticals Inc NOVEL siRNA COMPOUNDS FOR INHIBITING RTP801.
ES2565185T3 (en) * 2008-04-18 2016-04-01 Collplant Ltd. Methods of generation and use of procollagen
EP2293800B1 (en) 2008-06-06 2016-10-05 Quark Pharmaceuticals, Inc. Compositions and methods for treatment of ear disorders
EP2355737B1 (en) 2008-11-17 2021-08-11 Boston Scientific Scimed, Inc. Selective accumulation of energy without knowledge of tissue topography
WO2010111660A1 (en) * 2009-03-27 2010-09-30 Dexcom, Inc. Methods and systems for promoting glucose management
WO2011035065A1 (en) 2009-09-17 2011-03-24 Nektar Therapeutics Monoconjugated chitosans as delivery agents for small interfering nucleic acids
WO2011066475A1 (en) 2009-11-26 2011-06-03 Quark Pharmaceuticals, Inc. Sirna compounds comprising terminal substitutions
EP2510098B1 (en) 2009-12-09 2015-02-11 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the cns
WO2011084193A1 (en) 2010-01-07 2011-07-14 Quark Pharmaceuticals, Inc. Oligonucleotide compounds comprising non-nucleotide overhangs
JP2013523318A (en) 2010-04-09 2013-06-17 べシックス・バスキュラー・インコーポレイテッド Power generation and control equipment for tissue treatment
US9192790B2 (en) 2010-04-14 2015-11-24 Boston Scientific Scimed, Inc. Focused ultrasonic renal denervation
US8473067B2 (en) 2010-06-11 2013-06-25 Boston Scientific Scimed, Inc. Renal denervation and stimulation employing wireless vascular energy transfer arrangement
US9084609B2 (en) 2010-07-30 2015-07-21 Boston Scientific Scime, Inc. Spiral balloon catheter for renal nerve ablation
US9155589B2 (en) 2010-07-30 2015-10-13 Boston Scientific Scimed, Inc. Sequential activation RF electrode set for renal nerve ablation
US9408661B2 (en) 2010-07-30 2016-08-09 Patrick A. Haverkost RF electrodes on multiple flexible wires for renal nerve ablation
US9463062B2 (en) 2010-07-30 2016-10-11 Boston Scientific Scimed, Inc. Cooled conductive balloon RF catheter for renal nerve ablation
US9358365B2 (en) 2010-07-30 2016-06-07 Boston Scientific Scimed, Inc. Precision electrode movement control for renal nerve ablation
US8974451B2 (en) 2010-10-25 2015-03-10 Boston Scientific Scimed, Inc. Renal nerve ablation using conductive fluid jet and RF energy
US9220558B2 (en) 2010-10-27 2015-12-29 Boston Scientific Scimed, Inc. RF renal denervation catheter with multiple independent electrodes
US9028485B2 (en) 2010-11-15 2015-05-12 Boston Scientific Scimed, Inc. Self-expanding cooling electrode for renal nerve ablation
US9668811B2 (en) 2010-11-16 2017-06-06 Boston Scientific Scimed, Inc. Minimally invasive access for renal nerve ablation
US9089350B2 (en) 2010-11-16 2015-07-28 Boston Scientific Scimed, Inc. Renal denervation catheter with RF electrode and integral contrast dye injection arrangement
US9326751B2 (en) 2010-11-17 2016-05-03 Boston Scientific Scimed, Inc. Catheter guidance of external energy for renal denervation
US9060761B2 (en) 2010-11-18 2015-06-23 Boston Scientific Scime, Inc. Catheter-focused magnetic field induced renal nerve ablation
US9023034B2 (en) 2010-11-22 2015-05-05 Boston Scientific Scimed, Inc. Renal ablation electrode with force-activatable conduction apparatus
US9192435B2 (en) 2010-11-22 2015-11-24 Boston Scientific Scimed, Inc. Renal denervation catheter with cooled RF electrode
CN103298939A (en) 2010-12-06 2013-09-11 夸克医药公司 Double stranded oligonucleotide compounds comprising positional modifications
US20120157993A1 (en) 2010-12-15 2012-06-21 Jenson Mark L Bipolar Off-Wall Electrode Device for Renal Nerve Ablation
WO2012100095A1 (en) 2011-01-19 2012-07-26 Boston Scientific Scimed, Inc. Guide-compatible large-electrode catheter for renal nerve ablation with reduced arterial injury
US9579030B2 (en) 2011-07-20 2017-02-28 Boston Scientific Scimed, Inc. Percutaneous devices and methods to visualize, target and ablate nerves
US9186209B2 (en) 2011-07-22 2015-11-17 Boston Scientific Scimed, Inc. Nerve modulation system having helical guide
WO2013055826A1 (en) 2011-10-10 2013-04-18 Boston Scientific Scimed, Inc. Medical devices including ablation electrodes
WO2013055815A1 (en) 2011-10-11 2013-04-18 Boston Scientific Scimed, Inc. Off -wall electrode device for nerve modulation
US9420955B2 (en) 2011-10-11 2016-08-23 Boston Scientific Scimed, Inc. Intravascular temperature monitoring system and method
US9364284B2 (en) 2011-10-12 2016-06-14 Boston Scientific Scimed, Inc. Method of making an off-wall spacer cage
EP2768563B1 (en) 2011-10-18 2016-11-09 Boston Scientific Scimed, Inc. Deflectable medical devices
US9079000B2 (en) 2011-10-18 2015-07-14 Boston Scientific Scimed, Inc. Integrated crossing balloon catheter
AU2012332517B9 (en) 2011-11-03 2017-08-10 Quark Pharmaceuticals, Inc. Methods and compositions for neuroprotection
EP2776565A1 (en) 2011-11-08 2014-09-17 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the nervous system
CN108095821B (en) 2011-11-08 2021-05-25 波士顿科学西美德公司 Orifice renal nerve ablation
EP2779929A1 (en) 2011-11-15 2014-09-24 Boston Scientific Scimed, Inc. Device and methods for renal nerve modulation monitoring
US9119632B2 (en) 2011-11-21 2015-09-01 Boston Scientific Scimed, Inc. Deflectable renal nerve ablation catheter
US9265969B2 (en) 2011-12-21 2016-02-23 Cardiac Pacemakers, Inc. Methods for modulating cell function
CA2859989C (en) 2011-12-23 2020-03-24 Vessix Vascular, Inc. Methods and apparatuses for remodeling tissue of or adjacent to a body passage
US9433760B2 (en) 2011-12-28 2016-09-06 Boston Scientific Scimed, Inc. Device and methods for nerve modulation using a novel ablation catheter with polymeric ablative elements
US9050106B2 (en) 2011-12-29 2015-06-09 Boston Scientific Scimed, Inc. Off-wall electrode device and methods for nerve modulation
WO2013169927A1 (en) 2012-05-08 2013-11-14 Boston Scientific Scimed, Inc. Renal nerve modulation devices
US9890215B2 (en) * 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
WO2014032016A1 (en) 2012-08-24 2014-02-27 Boston Scientific Scimed, Inc. Intravascular catheter with a balloon comprising separate microporous regions
CA2880290C (en) 2012-09-12 2020-10-27 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide molecules targeting p53 and methods of use thereof
CN104780859B (en) 2012-09-17 2017-07-25 波士顿科学西美德公司 Self-positioning electrode system and method for renal regulation
US10549127B2 (en) 2012-09-21 2020-02-04 Boston Scientific Scimed, Inc. Self-cooling ultrasound ablation catheter
WO2014047411A1 (en) 2012-09-21 2014-03-27 Boston Scientific Scimed, Inc. System for nerve modulation and innocuous thermal gradient nerve block
CN104869930B (en) 2012-10-10 2020-12-25 波士顿科学国际有限公司 Renal neuromodulation apparatus and methods
US9956033B2 (en) 2013-03-11 2018-05-01 Boston Scientific Scimed, Inc. Medical devices for modulating nerves
WO2014143571A1 (en) 2013-03-11 2014-09-18 Boston Scientific Scimed, Inc. Medical devices for modulating nerves
US9808311B2 (en) 2013-03-13 2017-11-07 Boston Scientific Scimed, Inc. Deflectable medical devices
US10265122B2 (en) 2013-03-15 2019-04-23 Boston Scientific Scimed, Inc. Nerve ablation devices and related methods of use
AU2014237950B2 (en) 2013-03-15 2017-04-13 Boston Scientific Scimed, Inc. Control unit for use with electrode pads and a method for estimating an electrical leakage
US9827039B2 (en) 2013-03-15 2017-11-28 Boston Scientific Scimed, Inc. Methods and apparatuses for remodeling tissue of or adjacent to a body passage
JP2016523147A (en) 2013-06-21 2016-08-08 ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． Renal denervation balloon catheter with a riding-type electrode support
JP2016524949A (en) 2013-06-21 2016-08-22 ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． Medical device for renal nerve ablation having a rotatable shaft
US9707036B2 (en) 2013-06-25 2017-07-18 Boston Scientific Scimed, Inc. Devices and methods for nerve modulation using localized indifferent electrodes
US9833283B2 (en) 2013-07-01 2017-12-05 Boston Scientific Scimed, Inc. Medical devices for renal nerve ablation
EP3019106A1 (en) 2013-07-11 2016-05-18 Boston Scientific Scimed, Inc. Medical device with stretchable electrode assemblies
CN105377169B (en) 2013-07-11 2019-04-19 波士顿科学国际有限公司 Device and method for neuromodulation
US9925001B2 (en) 2013-07-19 2018-03-27 Boston Scientific Scimed, Inc. Spiral bipolar electrode renal denervation balloon
WO2015013205A1 (en) 2013-07-22 2015-01-29 Boston Scientific Scimed, Inc. Medical devices for renal nerve ablation
US10695124B2 (en) 2013-07-22 2020-06-30 Boston Scientific Scimed, Inc. Renal nerve ablation catheter having twist balloon
CN105473093B (en) 2013-08-22 2019-02-05 波士顿科学国际有限公司 Flexible circuit with the improved adhesion strength to renal nerve modulation sacculus
CN105555218B (en) 2013-09-04 2019-01-15 波士顿科学国际有限公司 With radio frequency (RF) foley's tube rinsed with cooling capacity
EP3043733A1 (en) 2013-09-13 2016-07-20 Boston Scientific Scimed, Inc. Ablation balloon with vapor deposited cover layer
WO2015057521A1 (en) 2013-10-14 2015-04-23 Boston Scientific Scimed, Inc. High resolution cardiac mapping electrode array catheter
US11246654B2 (en) 2013-10-14 2022-02-15 Boston Scientific Scimed, Inc. Flexible renal nerve ablation devices and related methods of use and manufacture
US9770606B2 (en) 2013-10-15 2017-09-26 Boston Scientific Scimed, Inc. Ultrasound ablation catheter with cooling infusion and centering basket
AU2014334574B2 (en) 2013-10-15 2017-07-06 Boston Scientific Scimed, Inc. Medical device balloon
US10945786B2 (en) 2013-10-18 2021-03-16 Boston Scientific Scimed, Inc. Balloon catheters with flexible conducting wires and related methods of use and manufacture
EP3060153A1 (en) 2013-10-25 2016-08-31 Boston Scientific Scimed, Inc. Embedded thermocouple in denervation flex circuit
WO2015103617A1 (en) 2014-01-06 2015-07-09 Boston Scientific Scimed, Inc. Tear resistant flex circuit assembly
CN106572881B (en) 2014-02-04 2019-07-26 波士顿科学国际有限公司 Substitution of the heat sensor on bipolar electrode is placed
US11000679B2 (en) 2014-02-04 2021-05-11 Boston Scientific Scimed, Inc. Balloon protection and rewrapping devices and related methods of use
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US11066465B2 (en) 2015-12-30 2021-07-20 Kodiak Sciences Inc. Antibodies and conjugates thereof
EP3548005A4 (en) 2016-11-29 2020-06-17 Puretech Health LLC Exosomes for delivery of therapeutic agents
KR101933217B1 (en) * 2017-12-28 2018-12-27 (주) 에빅스젠 Peptide for Inhibiting Skin Inflammation And Composition for Preventing or Treating Skin Inflammation Containing The Same
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009046A1 (en) * 1997-08-21 1999-02-25 Quark Biotech, Inc. Hypoxia-regulated genes

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4925678A (en) 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
US5080646A (en) 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5270030A (en) 1988-12-29 1993-12-14 Bio-Technology General Corp. Fibrin binding domain polypeptide and method of producing
US5225347A (en) 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Therapeutic ribozyme compositions and expression vectors
US5167616A (en) 1989-12-14 1992-12-01 Alza Corporation Iontophoretic delivery method
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5225182A (en) 1991-10-31 1993-07-06 Sharma Yash P Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system
US6372249B1 (en) * 1991-12-16 2002-04-16 Baylor College Of Medicine Senscent cell-derived inhibitors of DNA synthesis
EP1044987B1 (en) 1991-12-24 2006-02-15 Isis Pharmaceuticals, Inc. Gapped 2'-modified oligonucleotides
JPH08500481A (en) 1992-05-11 1996-01-23 リボザイム・ファーマシューティカルズ・インコーポレーテッド Methods and agents for inhibiting viral replication
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO1994024704A1 (en) * 1993-04-12 1994-10-27 Bolger Justin C Area bonding conductive adhesive preforms
GB9402161D0 (en) * 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
EP1709970A1 (en) 1995-04-27 2006-10-11 Abgenix, Inc. Human antibodies against EGFR, derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
BRPI9809391B8 (en) 1997-04-14 2021-05-25 Amgen Res Munich Gmbh process for producing an anti-human antigen receptor, human antibody and pharmaceutical composition
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US7973156B2 (en) 1997-08-21 2011-07-05 Quark Pharmaceuticals Inc. Hypoxia-regulated genes
US20030104973A1 (en) * 1997-08-21 2003-06-05 Quark Biotech, Inc. Hypoxia-regulated genes
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
DE19816395A1 (en) 1998-04-03 1999-10-07 Metagen Gesellschaft Fuer Genomforschung Mbh Human nucleic acid sequences from ovarian normal tissue
US6399178B1 (en) * 1998-07-20 2002-06-04 Amerasia International Technology, Inc. Rigid adhesive underfill preform, as for a flip-chip device
US6228585B1 (en) 1998-09-04 2001-05-08 Washington University Gene markers for chronic mucosal injury
DE19956568A1 (en) 1999-01-30 2000-08-17 Roland Kreutzer Method and medicament for inhibiting the expression of a given gene
WO2000077022A1 (en) 1999-06-11 2000-12-21 Human Genome Sciences, Inc. 50 human secreted proteins
AU4074500A (en) 1999-04-09 2000-11-14 Human Genome Sciences, Inc. 49 human secreted proteins
WO2001005998A1 (en) 1999-07-16 2001-01-25 Human Genome Sciences, Inc. Follistatin-3
AU7680300A (en) 1999-08-18 2001-03-13 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Human dna sequences
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
DE10160151A1 (en) 2001-01-09 2003-06-26 Ribopharma Ag Inhibiting expression of target gene, useful e.g. for inhibiting oncogenes, by administering double-stranded RNA complementary to the target and having an overhang
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
AU4592601A (en) 2000-03-21 2001-10-03 Millennium Predictive Medicine Novel genes, compositions, kits, and method for identification, assessment, prevention, and therapy of ovarian cancer
PT1309726E (en) 2000-03-30 2010-03-08 Whitehead Biomedical Inst Rna sequence-specific mediators of rna interference
AU2001249642A1 (en) 2000-04-06 2001-10-23 Genetics Institute, Llc Polynucleotides encoding novel secreted proteins
US6673545B2 (en) 2000-07-28 2004-01-06 Incyte Corporation Prostate cancer markers
US6727066B2 (en) 2000-07-28 2004-04-27 Incyte Corporation Genes expressed in treated human C3A liver cell cultures
CA2425827A1 (en) 2000-10-12 2002-04-18 Hyseq, Inc. Novel nucleic acids and polypeptides
US6673549B1 (en) * 2000-10-12 2004-01-06 Incyte Corporation Genes expressed in C3A liver cell cultures treated with steroids
US20020137077A1 (en) * 2000-10-25 2002-09-26 Hopkins Christopher M. Genes regulated in activated T cells
DK2813582T3 (en) 2000-12-01 2017-07-31 Max-Planck-Gesellschaft Zur Förderung Der Wss E V Small RNA molecules that mediate RNA interference
AU2002220920A1 (en) 2000-12-08 2002-06-18 Oxford Biomedica (Uk) Limited Method for identification of genes involved in specific diseases
US20030165864A1 (en) 2001-01-16 2003-09-04 Lasek Amy W. Genes regulated by DNA methylation in tumor cells
SG106054A1 (en) * 2001-04-17 2004-09-30 Micron Technology Inc Method and apparatus for package reduction in stacked chip and board assemblies
WO2003070910A2 (en) * 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20040019001A1 (en) 2002-02-20 2004-01-29 Mcswiggen James A. RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA
US7125663B2 (en) 2001-06-13 2006-10-24 Millenium Pharmaceuticals, Inc. Genes, compositions, kits and methods for identification, assessment, prevention, and therapy of cervical cancer
KR20040029380A (en) 2001-07-25 2004-04-06 시바 스페셜티 케미칼스 홀딩 인크. Perfluoroalkyl-substituted amines, acids, amino acids and thioether acids
WO2003010205A1 (en) * 2001-07-26 2003-02-06 Duke University Medical Center Genes induced by hypoxia
US20040063654A1 (en) 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
JP2003259877A (en) 2002-03-11 2003-09-16 Sumitomo Pharmaceut Co Ltd Marker for hepatic fibrosis disease and application of the same
WO2003101283A2 (en) 2002-06-04 2003-12-11 Incyte Corporation Diagnostics markers for lung cancer
EP1857547B2 (en) 2002-08-05 2020-12-02 Silence Therapeutics GmbH Further novel forms of interfering RNA molecules
JP2004121218A (en) 2002-08-06 2004-04-22 Jenokkusu Soyaku Kenkyusho:Kk Method for testing bronchial asthma or chronic obstructive pulmonary disease
EP2311980A1 (en) 2002-08-20 2011-04-20 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
JP2006516089A (en) 2002-10-02 2006-06-22 ジェネンテック・インコーポレーテッド Compositions and methods for tumor diagnosis and treatment
MXPA05004134A (en) * 2002-10-18 2005-10-05 Atugen Ag Factor involved in metastasis and uses thereof.
EP1578996A4 (en) 2002-10-18 2007-12-19 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
WO2004039956A2 (en) 2002-10-29 2004-05-13 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
KR20120038546A (en) * 2002-11-01 2012-04-23 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Compositions and methods for sirna inhibition of hif-1 alpha
US9150605B2 (en) * 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
EP2305813A3 (en) * 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
WO2004045545A2 (en) 2002-11-18 2004-06-03 Fox Chase Cancer Center Compositions and methods for the treatment of cancer, screening of putative anti-cancer compounds, and assessing cancer progression
ES2339113T3 (en) 2003-02-21 2010-05-17 University Of Utah Research Foundation VEGF PLASMY INDUCIBLE BY HYPOXIA FOR AN ISCHEMICAL DISEASE.
EP2233926A3 (en) 2003-04-01 2011-01-12 The Johns Hopkins University Breast Endothelial Cell Expression Patterns
WO2005016000A1 (en) 2003-08-05 2005-02-24 Avalon Pharmaceuticals Derivatives of cyclic quinone and uses thereof
KR101094617B1 (en) 2004-08-16 2011-12-15 사일런스 테라퓨틱스 아게 Therapeutic uses of inhibitors of rtp801
AU2005288522B2 (en) 2004-09-28 2012-06-28 Quark Pharmaceuticals, Inc. Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
DOP2007000015A (en) * 2006-01-20 2007-08-31 Quark Biotech Inc THERAPEUTIC USES OF RTP801 INHIBITORS
US7825099B2 (en) 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
US7910566B2 (en) 2006-03-09 2011-03-22 Quark Pharmaceuticals Inc. Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
US7723052B2 (en) * 2006-05-11 2010-05-25 Quark Pharmaceuticals, Inc. Screening systems utilizing RTP801
EP2026843A4 (en) * 2006-06-09 2011-06-22 Quark Pharmaceuticals Inc Therapeutic uses of inhibitors of rtp801l
DE102006031683A1 (en) * 2006-07-08 2008-01-17 Zf Friedrichshafen Ag Motor vehicle drive strand operating method, involves producing braking energy during implementation of high gear, and utilizing energy for starting engine, such that energy which is applied from motor for starting engine is minimized
EP2137205A2 (en) 2007-02-26 2009-12-30 Quark Pharmaceuticals, Inc. Inhibitors of rtp801 and their use in disease treatment
MX2010010303A (en) 2008-03-20 2010-10-20 Quark Pharmaceuticals Inc NOVEL siRNA COMPOUNDS FOR INHIBITING RTP801.
KR20100057710A (en) 2008-11-10 2010-06-01 삼성전자주식회사 Light emitting diodes and backlight unit having the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009046A1 (en) * 1997-08-21 1999-02-25 Quark Biotech, Inc. Hypoxia-regulated genes

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BRAASCH D.A. ET AL.: "RNA interference in mammalian cells by chemically modified RNA", BIOCHEMISTRY, vol. 42, 2003, pages 7967 - 7975, XP002328494 *
LEWIS M.: "Apoptosis as a potential mecanism of muscle cachexia in chronic obstructive pulmonary disease", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 166, 2002, pages 434 - 436, XP003011147 *
SUTER M. ET AL.: "Age-related macular degeneration", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 50, 15 December 2000 (2000-12-15), pages 39625 - 39630, XP002216156 *
TUDER R. ET AL.: "Apotosis and Emphysema The Missing Link", AM. J. RESPIR. CELL MOL. BIOL., vol. 28, 2003, pages 551 - 554, XP003011148 *
VIGNOLA A.M. ET AL.: "Evaluation of apoptosis of eosinophils, macrophages, and T lymphoicytes in mucosal biopsy specimens of patients with asthma and chronic bronchitis", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 103, April 1999 (1999-04-01), pages 563 - 573, XP005687094 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9433684B2 (en) 2008-08-19 2016-09-06 Nektar Therapeutics Conjugates of small-interfering nucleic acids
KR101672563B1 (en) 2008-10-22 2016-11-03 쿠아크 파마수티칼스 인코퍼레이티드 Methods for treating eye disorders
US9227956B2 (en) 2013-04-17 2016-01-05 Pfizer Inc. Substituted amide compounds

Also Published As

Publication number Publication date
US8168607B2 (en) 2012-05-01
AP2007003921A0 (en) 2007-02-28
WO2006023544A2 (en) 2006-03-02
NO342934B1 (en) 2018-09-03
NO20071240L (en) 2007-05-16
HK1111088A1 (en) 2008-09-05
US8309532B2 (en) 2012-11-13
EA012799B1 (en) 2009-12-30
EP1791568A2 (en) 2007-06-06
JP2008510019A (en) 2008-04-03
US20060217329A1 (en) 2006-09-28
EA200700333A1 (en) 2007-10-26
PL1791568T3 (en) 2013-01-31
US8642571B2 (en) 2014-02-04
US20110028532A1 (en) 2011-02-03
AU2005277508B2 (en) 2011-04-14
US7741299B2 (en) 2010-06-22
US20110117102A1 (en) 2011-05-19
IL243669B (en) 2018-11-29
KR100939274B1 (en) 2010-01-29
EP2319925A2 (en) 2011-05-11
KR101094617B1 (en) 2011-12-15
IL212985A0 (en) 2011-07-31
BRPI0514395A (en) 2008-06-10
IL181238A (en) 2016-02-29
CA2577423C (en) 2012-11-06
MX2007002043A (en) 2007-10-11
EP1791568A4 (en) 2008-12-10
CN101123994B (en) 2012-11-14
EP1791568B1 (en) 2012-08-15
TNSN07063A1 (en) 2008-06-02
US20130095117A1 (en) 2013-04-18
IL181238A0 (en) 2007-07-04
KR20090115901A (en) 2009-11-09
MA28802B1 (en) 2007-08-01
CN101123994A (en) 2008-02-13
JP4468989B2 (en) 2010-05-26
DK2319925T3 (en) 2018-11-05
NZ553162A (en) 2010-03-26
EP2319925B1 (en) 2018-07-25
KR20070050088A (en) 2007-05-14
AU2005277508A1 (en) 2006-03-02
CA2577423A1 (en) 2006-03-02
EP2319925A3 (en) 2011-09-21

Similar Documents

Publication Publication Date Title
WO2006023544A3 (en) Therapeutic uses of inhibitors of rtp801
WO2007084684A3 (en) Therapeutic uses of inhibitors of rtp801
WO2007141796A3 (en) Therapeutic uses of inhibitors of rtp801l
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
WO2004089286A3 (en) Novel compounds and compositions as protein kinase inhibitors
WO2005046603A3 (en) Pyridine compounds
WO2006047516A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2005048953A3 (en) Amide derivatives as kinase modulators
WO2008076754A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2007050793A3 (en) Methods and compositions for the treatment of marfan syndrome and associated disorders
WO2007016538A3 (en) Preparation and use of biphenyl amino acid derivatives for the treatment of obesity
WO2006044775A3 (en) Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
WO2008088524A3 (en) Thrombospondin-domain-deficient r-spondin 1 protein as gastrointestinal tract epithelial proliferation factor
WO2005099702A3 (en) R(-)-11-hydroxyaporphine derivatives and uses thereof
WO2007059341A3 (en) Pyrazolothiazole protein kinase modulators
TW200740808A (en) Inhibiteurs de proteines kinases
WO2005092062A3 (en) Compounds for neurodegenerative disorders
WO2005112923A3 (en) 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes
WO2006078336A3 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
JO2724B1 (en) 3-substituted-5- and 6-Aminoalkyl indole-2-carboxylic acid amides and related analogs as inhibitors of casein kinase I
WO2006078776A3 (en) Inhibitors and methods of treatment of cardiovascular diseases, and methods for identifying inhibitors
WO2005107464A3 (en) Compounds and compositions as cathepsin s inhibitors
UA92465C2 (en) Therapeutic uses of inhibitors of rtp801

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005277508

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 181238

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 553162

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: DZP2007000113

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 2007/01364

Country of ref document: ZA

Ref document number: 2007527969

Country of ref document: JP

Ref document number: 12007500391

Country of ref document: PH

Ref document number: 200701364

Country of ref document: ZA

Ref document number: 200700333

Country of ref document: EA

Ref document number: 2577423

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 9869

Country of ref document: GE

Ref document number: MX/a/2007/002043

Country of ref document: MX

Ref document number: AP/P/2007/003921

Country of ref document: AP

Ref document number: 07015821

Country of ref document: CO

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2005277508

Country of ref document: AU

Date of ref document: 20050816

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005277508

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1967/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005786796

Country of ref document: EP

Ref document number: 1020077006061

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: CR2007-008995

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 200580034968.5

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005786796

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0514395

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 212985

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 243669

Country of ref document: IL